36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
October 2025 in “International Journal of Molecular Sciences” Early intervention in patch-type alopecia may prevent progression to more severe forms by targeting immune pathways and preserving keratin.
27 citations
,
March 2018 in “Allergy and asthma proceedings” People with alopecia areata often have higher rates of allergies and autoimmune diseases.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.